Find out all the essential details about our platform and how it can serve your needs.
How to Place an Order?
You may place an order with us via e-mail to [email protected] or fax it either to the respective fax number for your country or to our general fax number: +32 16 50 90 45. An official order form is not required, a simple e-mail message will suffice. To place an order, please provide the following details: Mandatory details: Delivery address, Billing address, Catalogue number, description and size of the item(s) you wish to purchase, Quantity/number of units and a price or a price reference for the item(s). Optional details: VAT number of your organization (see the 'Invoicing' section below for more details), A number or other reference for your order that you wish to be mentioned on the invoice, delivery note, etc. Please note that Gentaur shall not be held responsible for incorrect information provided by the customer.
Payment Methods and Terms
Payments may be made via: Bank transfer, Credit card (Visa, MasterCard, American Express), Debit cards, Stripe, PayPal (so far for a limited list of countries). Payments may be remitted using the quotation and/or invoice number as a reference and the banking details that are available on the footer of the quotation or invoice. For credit card payments, our agents may send you a safe link for payment. In this case, please make sure to provide us with the correct e-mail address associated with the credit card with which the payment will be made. Alternatively, you may call us at the respective phone number for your country or at our general phone number: +32 16 58 90 45 and provide the credit card details. Please, provide the number of your order and/or the number of our quotation/invoice or other reference for the payment. Do not send your credit card details via e-mail. The general payment terms are 30 days net after the invoice is issued. However, Gentaur reserves the right to require a partial or full prepayment for orders when deemed necessary. For some custom services and made-to-order products, a non-refundable fee may be required in advance. All products remain a property of Gentaur until the invoice is paid in full.
Invoicing
Gentaur has locally registered offices with local VAT number in the following countries in Europe: Belgium, Bulgaria, France, Germany, Italy, Netherlands, Poland, and United Kingdom. If your billing address is in one of these countries, then the respective local Gentaur company will issue the invoice. If you are from a country in which Gentaur does not have a local office, the invoice will be issued from Gentaur Belgium. In this case we need your VAT number to issue an invoice without adding VAT, which will then be charged locally in your country. If you do not have a VAT number or do not wish to use it, the invoice will be issued with the Belgian VAT rate (21%). If you are from an organization which is VAT-free or has a reduced VAT rate, please enclose a copy of your VAT exemption certificate with each order. Customers from the USA can place orders through our website at the same prices converted into USD (a currency readily available in our menu). The goods for US customers will be delivered and invoiced locally via our subsidiary company Genprice Inc., located in San Jose, California.
Prices
The prices on the website are without VAT and do not include shipping and/or handling fees. Orders for products that are transported on dry ice are charged an additional fee. Orders for products that are considered hazardous for transportation are charged an additional fee. Prices are subject to change at any time and without prior notice. While every effort is made to keep the prices on our website up to date, in some instances some prices on the website may be outdated. In such cases Gentaur shall be under no obligation to process orders placed with an outdated price. Orders for items with outdated prices shall not be processed at their new prices without the explicit consent of the buyer. Our prices are the same for all countries, only the shipping fees and VAT or other local taxes may vary.
MTA's, Controlled Products, Export/Import Licenses, Dangerous Goods and Extra Fees
Some of our products are subjected to special regulations in terms of import/export, transportation, manner of use, etc. and various additional documents and/or fees may be required for ordering such products. While we make every effort to keep up to date information for such products on the respective product pages, due to the dynamic of the changes, implemented by the regulatory organs or the producers of these products, please, be advised that some information on these matters may be missing from the product pages. Should a situation like this occur with an already ordered product, we will inform you in due time and no extra fees will be applied to your order without your explicit consent. MTA (Material Transfer Agreement) may be required for some products that are a subject to intellectual property, but which may be continuously multiplied by the end user. Such products include, but are not limited to, some cell lines, some tissue cultures, some plasmids and other vectors or constructs. Controlled products may be different pure substances, chemical mixes, viral/bacterial suspensions and/or cultures, natural or synthetic toxins, products obtained from certain animal species that are subjected to special regulations and others. For the transportation and handling of such products we may require additional documents from you, such as MTAs, declarations on the end use, certification of the facility in which the goods will be used, etc. In some cases, extra fees for transportation and/or handling of such products may be needed.
Receipt and Performance of Product
Upon receiving the package, please inspect the products for transportation damage, loss of ice, leakages, breaks, etc. It is the responsibility of the customer to report immediately any of the above-listed issues. Our specialists will determine if the product is usable or if it should be replaced. For reporting performance issues, please send us the catalog number, the name and the Lot number of the product along with your results. Our technical support team will work with you to resolve the problem. Gentaur shall not be held liable for performance issues with products that were used beyond their expiration dates. Gentaur is under no obligation to replace goods that were damaged as a result of improper storage or handling after they were received by the customer.
Discounts and Samples
In most cases ordering 2 or more items from the same producer can be granted various discounts, depending on the respective quantity. Bulk orders are granted discounts regardless of whether the items are supplied by the same or different producers. Free samples are generally not offered but trial discounts in exchange for results and validation are almost always possible. Contact us and present your intended application to get a trial discount.
Looking for Products You Don't Find on the Website?
If you need a product that for some reason you do not find on our website, or even if you do not have a particular product in mind, do not hesitate to send us your questions at [email protected]. Our experienced specialists will find and send you a list of products suitable to your needs.
Patents and Other Intellectual Property
Gentaur has the utmost respect for any and all patents and intellectual property. We upload our product lists as they are provided to us by our suppliers and we are not able to check each individual product for patent or other intellectual property conflict. If you notice any product or other piece of information that violates a patent, trademark, or any other intellectual property that you own, please inform us immediately and we will take the necessary actions.
Withdrawal and Cancellation Requests
Eligible customers may submit withdrawal or cancellation requests through the designated Withdrawal / Cancellation Request form available on the Website. To submit a request, the customer must provide at least an email address, an order, quote, invoice or reference number, and the request type. Submission of a request does not automatically cancel an order, approve a refund, or confirm eligibility for withdrawal. Each request will be reviewed manually according to applicable law, order status, product type, customer status, and any relevant legal exemptions. Business-to-business orders, custom-made or specially ordered products, perishable products, temperature-sensitive products, refrigerated or frozen products, products transported on dry ice, hazardous or regulated products, and products already shipped, opened, consumed, or used may not be eligible for withdrawal or cancellation where allowed by applicable law.
Contacting Us
If you have any questions about this Policy, please contact us by email at [email protected].
Limitations of Use
All our products are intended for research laboratory use only and should not be used for diagnostics, for therapeutics, treatment or consumption by humans or animals or for other in-vivo uses. Our products should be operated in accordance with the provided instruction manuals and by qualified personnel. Gentaur and its subsidiaries shall not be held liable for issues caused by misuse of our products.
Jadeja RA, Mayani SV.
PMID:PPR1178661
Free PMC article
Abstract Green synthesis of metal oxide nanoparticles using plant-derived phytochemicals represents a sustainable and surface-engineered approach for developing functional nanomaterials. In the present study, an aqueous root extract of Butea monosperma was employed as a bio reducing and stabilizing agent for the synthesis of zinc oxide nanoparticles (ZnO NPs). Phytochemical profiling using qualitative assays, thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and LC–MS confirmed the presence of polyphenols, flavonoids, tannins, and triterpenoids, which are known to facilitate metal ion reduction and nanoparticle stabilization. UV–visible spectroscopy revealed a characteristic absorption edge in the UV region with an optical band gap of 3.69 eV, indicating nanoscale ZnO formation. Powder X-ray diffraction (PXRD) confirmed the formation of crystalline hexagonal wurtzite ZnO (JCPDS No. 36-1451) with an average crystallite size of 12–18 nm. Dynamic light scattering analysis showed a hydrodynamic diameter of 255.8 nm with a polydispersity index of 0.389, while a negative zeta potential (–25 mV) indicated moderate colloidal stability due to phytochemical surface capping. FTIR spectra demonstrated the involvement of hydroxyl and carbonyl functional groups in nanoparticle formation. SEM–EDX analysis confirmed nanoscale morphology and elemental purity (Zn 74.48 wt%, O 25.52 wt%). The synthesized ZnO NPs exhibited concentration-dependent antibacterial activity, with a maximum inhibition zone of 20 mm against Bacillus sp. and 15 mm against Escherichia coli at 1000 µg/mL. These findings establish a direct correlation between root phytochemical composition, nanoparticle physicochemical properties, and antimicrobial performance, demonstrating the potential of B. monosperma -mediated ZnO NPs as phytochemical-engineered antibacterial nanomaterials.
Patlan-Velázquez LF, González-Olivares LG, García-Garibay M, Alatorre-Santamaría S, Gómez-Ruiz L, Rodríguez-Serrano G, Carrasco-Navarro U, Cruz-Guerrero A.
Food Sci Nutr
PMID:42005323
Free PMC article
Requeson, a traditional Mexican whey cheese, represents a promising avenue for the valorization of dairy by-products. However, its functional potential remains underexplored. This study evaluated the enhancement of bioactive properties in Requeson cheese through lactic acid bacteria (LAB) fermentation, comparing two monocultures ( Lactobacillus delbrueckii subsp. bulgaricus NCFB 2772 and Streptococcus thermophilus SY-102) and a co-culture of both strains, cultured in sweet whey. Fermented whey was used to produce Requeson cheese, and peptide-rich extracts were analyzed for antioxidant activity (DPPH and FRAP), mineral-chelating capacity (Fe 2+ , Ca 2+ , Mg 2+ ), enzymatic inhibition (ACE-I, DPP-IV), and antimicrobial activity against E. coli , M. luteus , and L. innocua . Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to identify peptides, and their potential bioactivities were predicted using the UniDL4BioPep platform. The co-culture fermentation yielded significantly higher values across all assays, including antioxidant capacity (41.3 mg Trolox), ACE-I inhibition (31.8%), DPP-IV inhibition (14.2%), and antimicrobial activity. Several peptides with predicted antioxidant, antihypertensive, antidiabetic, and antimicrobial properties were exclusive to the co-culture formulation. These findings suggest that LAB co-culture fermentation of sweet whey is an effective strategy to develop peptide-enriched functional Requeson cheese with health-promoting properties. This approach supports the sustainable use of dairy by-products and contributes to the advancement of functional dairy products in the bioeconomy.
Camunas-Alberca SM, Bartolini F, Cermakova H, Sánchez-Illana Á, Perez-Guaita D, Cañadas-Miquel P, Gil-de-la-Fuente A, Galano JM, Durand T, Gradillas A, Barbas C.
Anal Chem
PMID:41997579
Free PMC article
Oxylipins are bioactive lipid mediators that play key roles in biological and pathological processes. Their remarkable chemical diversity makes their identification by untargeted LC-MS/MS analyses challenging. To date, effective solutions for their comprehensive characterization remain unavailable. Here, we present the first implementation of the recently refined Ion Identity Molecular Networking (IIMN) strategy to map the chemical space of oxylipins, together with a systematic evaluation of factors that hinder accurate annotation in MS/MS datasets. Building on recent mzmine software developments, we implemented a fully local strategy to perform the IIMN analysis without requiring web platforms or external tools. We established a high-quality MS/MS spectral library from 67 commercially available oxylipin standards using LC-MS data obtained in data-dependent acquisition mode. Integrating the detailed characterization of ion species generated during electrospray ionization into IIMN reduced network complexity. Across configurations, the modified cosine algorithm proved most effective for separating full-length from cyclized forms and for clustering oxylipins through structurally coherent relationships. Application of the IIMN workflow to mouse spleen extracts, in combination with our in-house and publicly available experimental MS/MS libraries, enabled the organization of oxylipins into molecular families, facilitating their structural characterization and the discovery of novel species. Although manual curation remained necessary for certain coeluting isomers and ambiguous fragments, the IIMN-based approach significantly improved network interpretability and understanding. Overall, this study establishes IIMN as a robust bioinformatic tool for decoding oxylipin diversity and provides a successful strategy for mapping their chemical space, characterizing them within samples, and discovering novel mediators in biological matrices. The new combined reference spectral library has been made publicly available and will serve as a valuable resource for future redox lipidomics research.
Msobo A, Maphari PW, Koorsen G, Singab ANB, Mhlongo MI.
In Silico Pharmacol
PMID:42005985
Free PMC article
The COVID-19 pandemic highlighted critical limitations in the speed, scalability and translational efficiency of conventional antiviral drug discovery. Although vaccines and repurposed antivirals have reduced disease severity, the continued emergence of SARS-CoV-2 variants and breakthrough infections underscores the need for sustained discovery of novel therapeutics. The main protease (Mpro), an essential and highly conserved enzyme required for viral replication remains a validated and attractive antiviral target. Medicinal plants represent a vast and underexplored source of structurally diverse bioactive compounds with antiviral potential; however, traditional plant-based drug discovery approaches are often constrained by reliance on ethnobotanical knowledge and fragmented screening workflows. This review critically examines emerging strategies that integrate machine learning, LC-MS-based metabolomics and network pharmacology to modernise medicinal plant-based antiviral discovery. We highlight how machine learning enables data-driven prioritisation of candidate compounds and plant species beyond well-studied taxa, while metabolomics provides experimental validation through comprehensive chemical profiling and dereplication. Molecular docking and molecular dynamics further refine candidate selection by evaluating binding modes and stability, whereas network pharmacology offers systems-level insight into multitarget and multipathway effects. Importantly, we discuss key limitations of these approaches, including data bias, model interpretability, and gaps between in silico prediction and experimental validation. By synthesising these methodologies into a unified computational-experimental pipeline, this review provides a critical framework for accelerating the discovery of plant-derived Mpro inhibitors and supports the development of resilient antiviral strategies for current and future pandemics.
Chen S, Wang M, Zeng Y, Li X, Zhong H, Liu Y, Tao Y, Yang X, Luo C, Chen S, Xiong H.
Eur J Med Chem
PMID:42001546
Free PMC article
Ubiquitin-specific protease 7 (USP7) is a key member of the deubiquitinating enzyme family. It is abnormally overexpressed in various malignancies, including breast cancer, chronic lymphocytic leukemia, and prostate cancer. By regulating pathways such as the p53-MDM2 signaling axis, USP7 promotes tumorigenesis and progression, making it a highly promising therapeutic target for anticancer treatment. Although multiple USP7 inhibitors have been reported, existing screening and evaluation assays exhibit limitations: the ubiquitin-phospholipase A 2 (Ub-PLA 2 ) assay frequently produces false-positive results, while the ubiquitin-rhodamine (Ub-Rho) assay is susceptible to interference from compound autofluorescence. To address this challenge, we developed a fluorescence polarization (FP) assay. This employs a rationally designed strategy that exhibits excellent characteristics, making it a simple-to-operate and cost-effective method, suitable for the evaluation of compound bioactivity against USP7. To further validate the practicality and reliability of this FP assay, we conducted a structure-based drug design campaign involving two rounds of systematic structural optimization, yielding 51 novel derivatives featuring pyrazolo[4,3-d]pyrimidine and piperidol scaffolds. Following FP evaluation and Ub-Rho enzyme activity validation, we performed a comprehensive structure-activity relationship (SAR) analysis. Ultimately, in vitro cellular assays identified three compounds (LC-U7-44, LC-U7-48, and LC-U7-50) that exhibit potent USP7 inhibitory activity alongside favorable cellular anti-proliferative effects. Overall, the established FP assay in this study closes a methodological gap in the evaluation of USP7 inhibitors, and the detailed SAR analysis provides a foundation for the further development of potent USP7 inhibitors.
